US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DEFIANCE DAILY TARGET 2X LONG HIMS ETF

25.03

+0.35001.42%

Post-market: 24.84-0.1900-0.76%19:54 EDT

Volume:187.31K

Turnover:4.66M

Market Cap:60.31M

PE:- -

High:25.84

Open:24.74

Low:24.15

Close:24.68

52wk High:391.58

52wk Low:12.38

Shares:2.41M

Float Shares:2.41M

Volume Ratio:0.68

T/O Rate:7.77%

Dividend:1.98

Dividend Rate:7.91%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Hims & Hers Shares up 2% After Telehealth Firm Urged FDA to Broaden Access to Some Peptides in Panel Meeting

THOMSON REUTERS

Peptides Could Soon Become Widely Available in the U.S. Here's What Happens Next.

Hims & Hers Health Inc : Citigroup Raises Target Price to $35 from $28

THOMSON REUTERS

Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99

Trump's FDA May Soon Back Peptides. Should You Buy In?

Hims & Hers Accounting Chief Exits

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

THOMSON REUTERS

Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%

Press Release: Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Hims & Hers Sets Second-quarter Results Release and Investor Call

Hims & Hers's Peptide Opportunity Remains in Focus

Hims & Hers Health is Maintained at Neutral by B of a Securities

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)

Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares for $261,540.56

Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Hims & Hers Health (HIMS) Secures $400 Million Financing, Is The Upside Already Priced In?

Simply Wall St.

Hims & Hers Health - Receivables Purchase Agreement Has Initial 364-day Term, Extendable by Written Agreement - SEC Filing

THOMSON REUTERS

Hims & Hers Signs USD 400 Million Receivables Purchase Facility with Jpmorgan Chase

Sector Update: Healthcare

MT Newswires Live

BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/HIMZ/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"HIMZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMZ\",,,,,undefined,":{"symbol":"HIMZ","market":"US","secType":"STK","nameCN":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","latestPrice":25.03,"timestamp":1789588800000,"preClose":24.68,"halted":0,"volume":187310,"hourTrading":{"tag":"盘后","latestPrice":24.84,"preClose":25.03,"latestTime":"19:54 EDT","volume":15866,"amount":396189.298958,"timestamp":1789602876369,"change":-0.19,"changeRate":-0.007591,"amplitude":0.009588},"delay":0,"changeRate":0.014181523500810431,"floatShares":2409608,"shares":2409608,"eps":0,"marketStatus":"Post-Mkt","change":0.35,"latestTime":"09-16 19:58:01 EDT","open":24.74,"high":25.8426,"low":24.145,"amount":4662578.77341,"amplitude":0.068784,"askPrice":25.25,"askSize":300,"bidPrice":24.84,"bidSize":200,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":24.68,"sharesOutstanding":57385000,"nav":26.5,"aum":63059585.5,"dividendRate":0.079105,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.88,"preClose":24.68,"latestTime":"09:29 EDT","volume":885,"amount":21994.76694,"timestamp":1789565345679,"change":0.2,"changeRate":0.008104,"amplitude":0.026207},"postHourTrading":{"tag":"盘后","latestPrice":24.84,"preClose":25.03,"latestTime":"19:54 EDT","volume":15866,"amount":396189.298958,"timestamp":1789602876369,"change":-0.19,"changeRate":-0.007591,"amplitude":0.009588},"volumeRatio":0.676819,"impliedVol":1.3081,"impliedVolPercentile":0.1793},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMZ\",,,,,undefined,":{"symbol":"HIMZ","floatShares":2409608,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.676819,"shares":2409608,"dividePrice":1.98,"high":25.8426,"amplitude":0.068784,"preClose":24.68,"low":24.145,"week52Low":12.3816,"pbRate":"--","week52High":391.58,"institutionHeld":0,"latestPrice":25.03,"committee":-0.2,"eps":0,"divideRate":0.079105,"volume":187310,"delay":0,"ttmEps":0,"open":24.74,"prevYearClose":81.06,"prevWeekClose":24.18,"prevMonthClose":28.37,"prevQuarterClose":48.7861,"fiveDayClose":25.12,"twentyDayClose":25.8,"sixtyDayClose":46.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIMZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-19","symbol":"HIMZ","defaultRemindTime":1773927000000,"type":"split","dateTimestamp":1773892800000,"forFactor":14,"toFactor":1,"ratio":14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIMZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIMZ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIMZ\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653049726","title":"Hims & Hers Shares up 2% After Telehealth Firm Urged FDA to Broaden Access to Some Peptides in Panel Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653049726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653049726?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:31","pubTimestamp":1784817111,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43P0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIMS","GLAM","HMYY","HIYY","BK4196","HIMY","HEAL","HIMZ","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723484","title":"Peptides Could Soon Become Widely Available in the U.S. Here's What Happens Next.","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653723484?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:18","pubTimestamp":1784812680,"startTime":"0","endTime":"0","summary":"If the FDA allows these seven peptides to be reclassified, that means compounding pharmacies can legally produce themA group of independent advisers to the FDA is meeting Thursday and Friday to vote w","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4196","HMYY","HIMS","GLAM","HIMY","HIYY","HEAL","HIMZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653499177","title":"Hims & Hers Health Inc : Citigroup Raises Target Price to $35 from $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2653499177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653499177?lang=en_us&edition=fundamental","pubTime":"2026-07-23 18:34","pubTimestamp":1784802859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43P0LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","GLAM","HIMY","HEAL","HIMS","HMYY","THNR","HIMZ","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245241","title":"Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245241","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653245241?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:31","pubTimestamp":1784579494,"startTime":"0","endTime":"0","summary":"Hims & Hers CFO Oluyemi Okupe disposes of 7,163 common shares valued at $229,075.99Hims & Hers Health CFO Oluyemi Okupe exercised stock options for 7,163 Class A shares at USD 5.01 on July 17.Okupe so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL767cfJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HIYY","THNR","HMYY","BK4196","HIMY","HEAL","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652823653","title":"Trump's FDA May Soon Back Peptides. Should You Buy In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652823653","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652823653?lang=en_us&edition=fundamental","pubTime":"2026-07-18 09:31","pubTimestamp":1784338260,"startTime":"0","endTime":"0","summary":"The small-chain amino acids have picked up online fans, particularly in the workout and wellness worlds. One big backer: HHS Secretary Robert F. Kennedy Jr. Some on Wall Street see a potentially large","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","BK4007","HIYY","NVOX","HMYY","BK4588","HIMS","IE00BKVL7J92.USD","HIMY","BK4585","BK4196","BK4599","NVO","LU1093756168.USD","NVOH","THNR","OZEM","BK4532","HEAL","LU0154236417.USD","LU1093756325.SGD","PPH","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652238849","title":"Hims & Hers Accounting Chief Exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2652238849","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652238849?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:30","pubTimestamp":1784320200,"startTime":"0","endTime":"0","summary":"Hims & Hers Chief Accounting Officer Irene Becklund is departing the health and wellness platform effective Oct. 9, with CFO Yemi Okupe taking on interim CAO duties. Becklund joined in 2019 as the company's first Controller and is credited with building much of its financial reporting infrastructure. Her tenure spans several major corporate milestones, including Hims & Hers's IPO, strategic acquisitions, and international expansion. She'll serve as an adviser for several months to assist with the transition while the company searches for a permanent replacement.This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. Dow Jones NewswiresJuly 17, 2026 16:30 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","HIYY","HIMZ","HIMS","HMYY","HEAL","HIMY","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652128076","title":"Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2652128076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652128076?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:17","pubTimestamp":1784319420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA3QRRTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THNR","HEAL","HMYY","HIMZ","HIMS","HIMY","HIYY","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652424679","title":"Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652424679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652424679?lang=en_us&edition=fundamental","pubTime":"2026-07-17 03:55","pubTimestamp":1784231711,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Hims and Hers Health (HIMS), with shares down $3.48 near $33.70. Options volume roughly in line with ave...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-hims-and-hers-health-with-shares-down-9-35-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-hims-and-hers-health-with-shares-down-9-35-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","HIYY","HEAL","HIMS","HMYY","HIMY","HIMZ","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651614124","title":"Press Release: Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651614124","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651614124?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:23","pubTimestamp":1783974180,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO--(BUSINESS WIRE)--July 13, 2026--Hims & Hers Health, Inc. (\"Hims & Hers\", NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","HIYY","HIMZ","HIMY","HMYY","BK4196","THNR","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651419401","title":"Hims & Hers Sets Second-quarter Results Release and Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2651419401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651419401?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:05","pubTimestamp":1783973156,"startTime":"0","endTime":"0","summary":"Hims & Hers sets second-quarter results release and investor callHims & Hers schedules second-quarter 2026 results for Aug. 10, 2026.Conference call set for Aug. 10, 2026 at 5 p.m. ET, following the m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL8fblfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HMYY","HIMS","HIMY","BK4196","HIMZ","THNR","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650755249","title":"Hims & Hers's Peptide Opportunity Remains in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2650755249","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650755249?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:14","pubTimestamp":1783613640,"startTime":"0","endTime":"0","summary":"1214 ET - Hims & Hers Health is likely to beat estimates and raise its full-year guidance when it reports second-quarter results, but its potential opportunity in peptides is the biggest thing on investors' minds, Truist Securities analysts say in a note. The analysts point to credit-card data from June, which shows strong trends in the telehealth company's GLP-1 business as the rest of its business remains stable, they say. However, the stock has gained lately due to enthusiasm around the company's potential in peptides, making for a tough risk-reward setup for shares heading into the Food and Drug Administration's advisory committee meeting later this month, which will consider several peptides, the analysts say. Even if the committee gives a favorable recommendation, Hims likely wouldn't see any meaningful revenue boost from a potential peptide offering before 2028, the analysts say.  Dow Jones NewswiresJuly 09, 2026 12:14 ET Copyright  2026 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMZ","HMYY","HIMS","BK4196","HIYY","HEAL","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650296659","title":"Hims & Hers Health is Maintained at Neutral by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2650296659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650296659?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:38","pubTimestamp":1783597080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HIMS/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 07:38 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","HIYY","HIMZ","HIMS","HMYY","HEAL","HIMY","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923855","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923855?lang=en_us&edition=fundamental","pubTime":"2026-07-09 17:50","pubTimestamp":1783590627,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS) and Tarsus Pharmaceutica...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-and-tarsus-pharmaceuticals-tars-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-and-tarsus-pharmaceuticals-tars-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TARS","HEAL","HIYY","HIMY","HIMZ","HIMS","HMYY","THNR","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649865930","title":"Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares for $261,540.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2649865930","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649865930?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:21","pubTimestamp":1783455682,"startTime":"0","endTime":"0","summary":"Hims & Hers CFO Oluyemi Okupe disposes of 7,163 common shares for $261,540.56Hims & Hers CFO Oluyemi Okupe sold 7,163 Class A shares at an average price of $36.49 on July 6, 2026.The sale followed the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL9VLQww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares for $261,540.56","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","HIYY","HIMZ","HIMY","HMYY","BK4196","THNR","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649690202","title":"Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649690202","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649690202?lang=en_us&edition=fundamental","pubTime":"2026-07-05 14:00","pubTimestamp":1783231200,"startTime":"0","endTime":"0","summary":"Many Americans would love a drug that makes them fitter, sharper, and more attractive. The peptides industry aims to oblige, and sales may soon be off to the races, courtesy of the Trump Administratio","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","HIMZ","BK4588","LU1093756325.SGD","HIYY","PPH","OZEM","BK4599","HIMY","IE00BKVL7J92.USD","BK4007","NVO","HIMS","LU0154236417.USD","THNR","LU1093756168.USD","NVOH","IE00BZ1G4Q59.USD","HEAL","NVOX","BK4196","HMYY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503293","title":"Hims & Hers Health (HIMS) Secures $400 Million Financing, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503293","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648503293?lang=en_us&edition=fundamental","pubTime":"2026-07-02 14:41","pubTimestamp":1782974499,"startTime":"0","endTime":"0","summary":"Hims & Hers Health (HIMS) is back in focus after securing a $400 million financing arrangement with JPMorgan Chase Bank. This move improves liquidity while regulatory scrutiny of its peptide ambitions intensifies.\nSee our latest analysis for Hims & Hers Health.\nAt a share price of $37.57, Hims & Hers Health has seen strong short term momentum, with a 1 month share price return of 35.34% and 90 day share price return of 96.29%, while the 1 year total shareholder return declined 20.84% but the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/hims-hers-health-hims-secures-400-million-financing-is-the-u","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/hims-hers-health-hims-secures-400-million-financing-is-the-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HIMY","HIMS","BK4196","HMYY","HIMZ","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648256529","title":"Hims & Hers Health - Receivables Purchase Agreement Has Initial 364-day Term, Extendable by Written Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2648256529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648256529?lang=en_us&edition=fundamental","pubTime":"2026-07-02 05:03","pubTimestamp":1782939813,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nFWN433146:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIMS","HIMZ","HMYY","BK4196","HIYY","HIMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648529254","title":"Hims & Hers Signs USD 400 Million Receivables Purchase Facility with Jpmorgan Chase","url":"https://stock-news.laohu8.com/highlight/detail?id=2648529254","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648529254?lang=en_us&edition=fundamental","pubTime":"2026-07-02 05:03","pubTimestamp":1782939803,"startTime":"0","endTime":"0","summary":"Hims & Hers signs USD 400 million receivables purchase facility with JPMorgan ChaseHims & Hers subsidiaries XeCare, Apostrophe Pharmacy entered a Master Receivables Purchase Agreement with JPMorgan on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL96VZhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU0203347892.USD","BK4533","JPMO","JPX","LU0868494708.USD","LU0106831901.USD","IE0034235295.USD","LU0208291251.USD","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU0683600562.USD","LU1366192091.USD","LU2756315318.SGD","HIYY","IE00BJLML261.HKD","LU2023250843.SGD","IE00B1XK9C88.USD","LU1162221912.USD","LU1496350502.SGD","LU0265550946.USD","BK4550","LU0170899867.USD","LU0211331839.USD","LU0689472784.USD","LU1974910355.USD","SG9999002224.SGD","IE00BJTD4V19.USD","IE00BJTD4N35.SGD","LU0882574139.USD","LU1548497426.USD","LU2552382058.USD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","JPO","LU0265550359.USD","LU1670628061.USD","IE00BFXG1179.USD","LU0106261372.USD","SG9999002232.USD","LU0006306889.USD","LU2505996681.GBP","LU0203345920.USD","LU2357305700.SGD","LU2430703178.SGD","IE0034235188.USD","LU2237443895.HKD","LU1145028129.USD","LU2054465674.USD","LU1244550577.SGD","HIMZ","IE0034235303.USD","LU0496365809.HKD","LU1119994496.HKD","LU1261432733.SGD","LU2756315664.SGD","IE00B775SV38.USD","BK4207","BK4588","LU1244550494.USD","LU0820561909.HKD","LU0971096721.USD","IE00BBT3K403.USD","BK4534","LU2746668974.SGD","LU2264538146.SGD","LU0211327993.USD","BK4581","IE00BKVL7J92.USD","LU1894683264.USD","LU0149725797.USD","LU0640476718.USD","IE00BDRTCR15.USD","IE00BYXW3230.USD","LU1551013425.SGD","LU2505996509.AUD","LU0256863811.USD","LU0211328371.USD","LU0070302665.USD","LU2211815571.USD","BK4566","BK4585","LU2430703095.HKD","LU1551013342.USD","LU0345770308.USD","LU0234572021.USD","LU0868494617.USD","LU2552382132.HKD","LU1894683348.USD","LU0238689110.USD","IE00BZ1G4Q59.USD","LU2381873111.SGD","LU0820561818.USD","LU2244417387.USD","LU0345769128.USD","LU0820562030.AUD","LU2237443465.HKD","LU0345769631.USD","IE00BDCRKT87.USD","LU1084165304.USD","LU1116320901.HKD","LU0787776722.HKD","BK4196","BK4516","LU2023250330.USD","LU1668664300.SGD","LU0187121727.USD","HMYY","LU2237443382.USD","LU0345770993.USD","LU0310799852.SGD","LU2430703251.USD","IE00BKDWB100.SGD","LU0964807845.USD","LU1116320737.USD","LU2237443549.SGD","IE00BN8TJ469.HKD","LU0211326839.USD","LU1064131342.USD","IE00B3S45H60.SGD","LU1267930490.SGD","LU1032466523.USD","LU2237443622.USD","LU0943347566.SGD","LU1720051108.HKD","LU0234570918.USD","LU1496350171.SGD","JPM","LU2462157665.USD","LU1917777945.USD","LU0256863902.USD","LU0320765489.SGD","LU0859254822.USD","LU1720051017.SGD","LU2746668461.USD","LU1914381329.SGD","LU2456880835.USD","LU2552382215.SGD","LU2592432038.USD","IE00BHPRN162.USD","LU2213496289.HKD","LU1629891620.HKD","LU1363072403.SGD","HIMY","LU0251132253.USD","LU2236285917.USD","LU2023250504.SGD","LU2106854487.HKD","LU0048584097.USD","LU0211326755.USD","LU0323591593.USD","LU1280957306.USD","LU1670627923.USD","LU2237443978.SGD","LU0267386448.USD","LU2242649171.HKD","LU2417539215.USD","BK4504","LU0215105999.USD","LU0417517546.SGD","LU0942090050.USD","LU2357627491.SGD","LU1244550221.USD","LU1988902786.USD","HIMS","LU0976567544.SGD","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648540507","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2648540507","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648540507?lang=en_us&edition=fundamental","pubTime":"2026-07-02 01:19","pubTimestamp":1782926397,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF  adding 0.4%.The iShares Biotechnology ETF  was fractionally higher.In corporate news, Hims & Hers Health  shares jumped past 8% after BofA Securities lifted the company's price target to $36 from $25, while keeping its neutral rating.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","HMYY","IBB","XBI","LU0029874061.USD","HIMY","BK4581","HIMZ","BK4588","BK4585","BK4196","LU0128526141.USD","HIMS","LABU","HIYY","HCSG","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648940549","title":"BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2648940549","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648940549?lang=en_us&edition=fundamental","pubTime":"2026-07-01 22:06","pubTimestamp":1782914817,"startTime":"0","endTime":"0","summary":"Hims & Hers Health (HIMS) has an average rating of Hold and mean price target of $29.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HMYY","HIMS","HIMZ","HIYY","BK4196","HIMY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}